In vitro Drug Release of Novel Polysaccharide 5-FU conjugate

Abstract

As the second greatest cause of mortality in the US, cancer is a serious global public health issue. Advanced-stage disease and mortality rates may rise as a result of delayed diagnosis and treatment. 5-fluorouracil (5-FU) is a popular chemotherapeutic medication used to treat a range of malignancies, including colorectal, breast, and head and neck cancers. The creation of 5-FU conjugates, in which the medication is chemically bonded to polymers, nanoparticles, or other macromolecular carriers, is one possible strategy.  An essential first step in assessing 5-FU's release properties from its conjugate formulation is the in-vitro diffusion research. The results from this study can be used to create release profiles, which can then be examined to learn more about the mechanisms and kinetics of release, including diffusion, swelling, and erosion. The results obtained above drug release follows first order kinetics as witnessed with high R² value (0.955). This indicates drug release is concentration dependent. The results of alkaline hydrolysis of CS-FUAC have shown that the 5-FU have good ability to form conjugation with chitosan.